Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells

Oncogene

Volumn 26, Issue 20, 2007, Pages 2860-2872

  Li, J ^a   Wood III, W H ^a   Becker, K G ^a   Weeraratna, A T ^a   Morin, P J ^a,b,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Cisplatin; Connexin; Expression profiling; Microarrays; Ovarian cancer; p53

Indexed keywords

CISPLATIN; CONNEXIN 43; OLIGONUCLEOTIDE; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UNINDEXED SEQUENCE; UPREGULATION; WILD TYPE;

CISPLATIN; CLUSTER ANALYSIS; CONNEXIN 43; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247862218     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210086     Document Type: Article

References (51)

1. Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, Kort E et al. (2004). Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res 10: 8204-8213.
2. Amundson SA, Do KT, Vinikoor L, Koch-Paiz CA, Bittner ML, Trent JM et al. (2005). Stress-specific signatures: expression profiling of p53 wild-type and -null human cells. Oncogene 24: 4572-4579.
3. Azzam EI, de Toledo SM, Gooding T, Little JB. (1998). Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of alpha particles. Radiat Res 150: 497-504.
4. Azzam EI, de Toledo SM, Little JB. (2003). Expression of CONNEXIN43 is highly sensitive to ionizing radiation and other environmental stresses. Cancer Res 63: 7128-7135.
5. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B et al. (1993). Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678-684.
6. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L et al. (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269.
7. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V et al. (1997). p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230-235.
8. Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB. (2006). Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 58: 384-395.
9. Dalton WS. (1999). The tumor microenvironment as a determinant of drug response and resistance. Drug Resist Updat 2: 285-288.
10. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Sire E, Arzani D et al. (1997). DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer 76: 474-479.
11. Dong Y, Walsh MD, McGuckin MA, Cummings MC, Gabrielli BG, Wright GR et al. (1997). Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 74: 407-415.
12. Einhorn LH. (2002). Curing metastatic testicular cancer. Proc Natl Acad Sci USA 99: 4592-4595.
13. el-Fouly MH, Trosko JE, Chang CC. (1987). Scrape-loading and dye transfer. A rapid and simple technique to study gap junctional intercellular communication. Exp Cell Res 168: 422-430.
14. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC et al. (1995). The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-1228.
15. Fernstrom MJ, Koffler LD, Abou-Rjaily G, Boucher PD, Shewach DS, Ruch RJ. (2002). Neoplastic reversal of human ovarian carcinoma cells transfected with connexin43. Exp Mol Pathol 73: 54-60.
16. Filmus J. (2001). Glypicans in growth control and cancer. Glycobiology 11: 19R-23R.
17. Hawkins DS, Demers GW, Galloway DA. (1996). Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898.
18. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. (1996). The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184.
19. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. (2001). Coordinately up-regulated genes in ovarian cancer. Cancer Res 61: 3869-3876.
20. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS et al. (2004). Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10: 272-284.
21. Kartalou M, Essigmann JM. (2001). Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43.
22. Kerley-Hamilton JS, Pike AM, Li N, Direnzo J, Spinella MJ. (2005). A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene 24: 6090-6100.
23. Koivusalo R, Krausz E, Ruotsalainen P, Helenius H, Hietanen S. (2002). Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 62: 7364-7371.
24. Kopf-Maier P, Muhlhausen SK. (1992). Changes in the cytoskeleton pattern of tumor cells by cisplatin in vitro. Chem Biol Interact 82: 295-316.
25. Li C, Wong WH. (2001). Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98: 31-36.
26. Lin HC, Huber R, Schlessinger D, Morin PJ. (1999). Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 59: 807-810.
27. Lin JH, Yang J, Liu S, Takano T, Wang X, Gao Q et al. (2003). Connexin mediates gap junction-independent resistance to cellular injury. J Neurosci 23: 430-441.
28. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
29. Lowe SW, Ruley HE, Jacks T, Housman DE. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
30. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L et al. (1999). Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13: 2207-2217.
31. Moorehead RA, Singh G. (2000). Influence of the protooncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 59: 337-345.
32. Morin PJ. (2003). Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 6: 169-172.
33. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, MutohM et al. (1997). Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300.
34. Ozols RF, Young RC. (1984). Chemotherapy of ovarian cancer. Semin Oncol 11: 251-263.
35. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI. (2000). Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 57: 503-511.
36. Pestell KE, Medlow CJ, Titley JC, Kelland LR, Walton MI. (1998). Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 77: 913-918.
37. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U et al. (2001). Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984-2997.
38. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP et al. (2005). Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92: 1149-1158.
39. Ryan KM, Phillips AC, Vousden KH. (2001). Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332-337.
40. Sax JK, El-Deiry WS. (2003). p53 downstream targets and chemosensitivity. Cell Death Differ 10: 413-417.
41. 14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol Pharmacol 66: 789-793.
42. Sherman-Baust CA, Weeraratna AT, Rangel LBA, Pizer ES, Cho KR, Schwartz DR et al. (2003). Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3: 377-386.
43. Siddik ZH. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
44. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T et al. (2005). Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11: 2625-2636.
45. Tanaka T, Yamasaki H, Mesnil M. (2001). Induction of a bystander effect in HeLa cells by using a bigenic vector carrying viral thymidine kinase and connexin32 genes. Mol Carcinog 30: 176-180.
46. Thiel G, Cibelli G. (2002). Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193: 287-292.
47. Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L, Pendyala L. (2005). Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 14: 925-932.
48. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT et al. (2004). Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23: 474-482.
49. Wernyj RP, Morin PJ. (2004). Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat 7: 227-232.
50. Whiteside MA, Chen DT, Desmond RA, Abdulkadir SA, Johanning GL. (2004). A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene 23: 744-752.
51. Wu GS, El-Deiry WS. (1996). Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 2: 623-633.